Hope in the Long Road Toward the Development of a Therapeutic Human Papillomavirus Vaccine.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 26968203.
- Also identified by DOI 10.1158/1078-0432.CCR-16-0216.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A pool of long synthetic peptides derived from HPV16 proteins induce objective partial or complete histologic regression of lesions in more than 50% of patients with high-grade vulvar (VuVIN3) and vaginal intraepithelial neoplasia (VaIN3). The intensity of T-cell response induced by the vaccine was correlated with clinical response. Clin Cancer Res; 22(10); 2317-9. ©2016 AACRSee related article by van Poelgeest et al., p. 2342.
Medical subject headings
- Papillomaviridae
- Papillomavirus Infections
- Papillomavirus Vaccines